Nina Shah, MD

Associate Professor
University of California San Francisco
San Francisco, California

Dr. Nina Shah is an Associate Professor in the Division of Hematology-Oncology at University of California San Francisco. Her research focuses on multiple myeloma, specifically immunotherapy and cellular therapy. Dr. Shah performed the first-in-human clinical trial of umbilical cord blood-derived natural killer cell therapy for myeloma and is currently one of the three lead principal investigators (PI) for the multi-center BMT CTN 1401 dendritic cell vaccine trial for myeloma patients. In addition, she is involved in numerous CAR-T and immunotherapy protocols.

Dr. Shah is also interested in outcomes research for myeloma patients undergoing autologous transplantation, she has led a randomized trial to determine the impact of stem cell dose on symptoms in this patient population and has also published on patient reported outcomes in this clinical context. Dr. Shah is heavily involved in the myeloma research community and led the effort to define myeloma-transplant practice guidelines for the American Society of Blood and Marrow Transplant (ASBMT). She serves as a co-chair for the Plasma Cell Disorders and Adult Solid Tumors Working Committee at the Center for International Blood & Marrow Transplant Research (CIBMTR).

Last modified: March 23, 2021